Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Cancer » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Time-Delay Systems: Concepts, Design and Stability Analysis
$85.50
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Experimental Leukemia: History, Biology and Genetics
02.Cancer Metastasis Research: Pathological Insight
03.Eye Cancer Research Progress
04.Mesothelioma from Bench Side to Clinic
05.Photodynamic Therapy: New Research
06.Cancer and Stem Cells
07.Oncology Social Work Practice in the Care of Breast and Ovarian Cancer Survivors
08.Progress in Oral Cancer Research
09.New Research on Cutaneous Lymphomas
10.Aromatase Inhibitors: Types, Mode of Action and Indications
Notifications more
NotificationsNotify me of updates to Cardiotoxicity of Chemotherapeutic Agents
Tell A Friend
 
Tell someone you know about this product.
Cardiotoxicity of Chemotherapeutic Agents
Retail Price: $160.00
10% Online Discount
You Pay:

$144.00
Editors: Gregg M. Lanier, Jalaj Garg and Neeraj Shah (Lehigh Valley Health Network, Allentown, USA, and others)
Book Description:
Cardiotoxicity is a well-established complication of antineoplastic agents. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies. There is a growing need for better testing platforms, both for cardiovascular toxicity screening and for elucidating mechanisms of cardiotoxicity of approved cancer therapies.

Our book is a comprehensive summary of information of numerous antineoplastic agents and their cardiovascular adverse effects. Cardiac oncology is an exciting and ever-changing field, and we have attempted to synthesize information from all the major and relevant studies in the field in our book.

The authors hope that their book serves as a valuable reference in the field of cardiac oncology for the clinicians who are actively involved in the management of patients receiving antineoplastic agents, including primary care physicians, cardiologists, cardiology fellows in training and oncologists. (Imprint: Nova Biomedical)


We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.


Table of Contents:
Preface

Chapter 1. Introduction: Cardiotoxicity of Chemotherapeutic Agents (pp. 1-4)
(Jalaj Garg MD FESC, Neeraj Shah MD MPH and Gregg M. Lanier MD, Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 2. Alkylating Agents (pp. 5-12)
(Jalaj Garg MD, Varun Mittal MD, Neeraj Shah MD, Abhishek Sharma, Vidhu Anand MD and Gregg M. Lanier MD, Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 3. Antimetabolites (pp. 13-32)
(Jalaj Garg MD FESC, Varun Mittal MD, Neeraj Shah MD MPH, Abhishek Sharma MD, Vidhu Anand MD and Gregg M. Lanier MD, Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 4. Antitumor Antibiotics: Bleomycin and Mitoxantrone (pp. 33-38)
(Rahul Gupta MD, Rahul Chaudhary MD, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD, Queens Cardiac Care, Queens, USA, and others)

Chapter 5. Antitumor Antibiotics: Anthracyclines, a Mechanism of Cardiotoxicity (pp. 39-52)
(Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M Lanier MD, Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

Chapter 6. Antitumor Antibiotics: Anthracyclines, Cardiotoxicity and Associated Risk Factors (pp. 53-68)
(Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD, Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

Chapter 7. Antitumor Antibiotics: Anthracyclines and Minimizing Cardiotoxicity (pp. 69-88)
(Rahul Chaudhary MD, Rahul Gupta MBBS, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD, Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

Chapter 8. Antitumor Antibiotics: Newer Anthracyclines (pp. 89-100)
(Rahul Gupta MD, Rahul Chaudhary MD, Vidhu Anand MD, Abhishek Sharma MD, Gurprataap Singh Sandhu MD and Gregg M. Lanier MD. Queens Cardiac Care, Queens, USA, and others)

Chapter 9. Microtubule Inhibitors (pp. 101-120)
(Brijesh Patel DO, Rahul Gupta MBBS, Jalaj Garg MD FESC, Naveen Sablani MD MS, Ronak Patel MD FACC and Gregg M. Lanier MD, Division of Cardiology, Lehigh valley Health Network, Allentown, USA, and others)

Chapter 10. Hormonal Therapy (pp. 121-136)
(Jalaj Garg MD FESC, Mahek Shah MD, Rahul Chaudhary MD, Rahul Gupta MBBS, Ronak Patel MD FACC and Gregg M Lanier MD, Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 11. Immunotherapy (pp. 137-152)
(Nayan Agarwal MD, Rahul Gupta MBBS, Abhishek Sharma MD, Rudhir Tandon MD, Rahul Chaudhary MD, Raman Dusaj MD and Gregg M. Lanier MD, Division of Cardiology, University of Florida, Gainesville, USA, and others)

Chapter 12. Monoclonal Antibodies (pp. 153-176)
(Jalaj Garg MD FESC, Nayan Agarwal MD, Neeraj Shah MD MPH, Rahul Gupta MBBS, Nainesh C Patel MD FACC and Gregg M Lanier MD FACC, Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 13. Tyrosine Kinase Inhibitors (pp. 177-192)
(Mahek Shah MD, Rahul Gupta MBBS, Rahul Chaudhary MD, Nainesh C Patel MD FACC and Gregg M Lanier MD, Division of Cardiology, Lehigh Valley Health Network, Allentown, USA, and others)

Chapter 14. Topoisomerase-1 Inhibitors and Miscellaneous Drugs (pp. 193-204)
(Rahul Chaudhary MD, Nikhil Mukhi MD, Rahul Gupta MBBS, Jalaj Garg MD FESC, Philip Carson MD, Neeraj Shah MD MPH, Gregg M. Lanier MD, Division of Medicine, Sinai Hospital of Baltimore, USA, and others)

About the Editors (pp. 205)

Index (pp. 209)

Total Pages: 214

   Series:
      Cancer Etiology, Diagnosis and Treatments
      Cardiology Research and Clinical Developments
   Binding: Hardcover
   Pub. Date: 2017 - 2nd Quarter
   Pages: 6x9 - NBC-R
   ISBN: 978-1-53612-119-3
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Chaliapin and the Jews: The Question of Chaliapin's Purported Antisemitism
02.The Humanities: Past, Present and Future
03.The Poles: Myths and Reality
04.Child-Rearing: Practices, Attitudes and Cultural Differences
05."A Home Away from Home": A Community of International and South African University Students
06.Palliative Care: Oncology Experience from Hong Kong
07.The Enigma of Autism: Genius, Disorder or Just Different?
08.The Collector Mentality: Modernization of the Hunter-Gatherer
09.Face Processing: Systems, Disorders and Cultural Differences
10.Occurrences, Structure, Biosynthesis, and Health Benefits Based on Their Evidences of Medicinal Phytochemicals in Vegetables and Fruits. Volume 8
11.Crystal Growth: Concepts, Mechanisms and Applications
12.The Economic, Social and Political Impact of Mining on Akyem Abuakwa from the Pre-Colonial Era up to 1943

Nova Science Publishers
© Copyright 2004 - 2017

Cardiotoxicity of Chemotherapeutic Agents